This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Sangamo Rises on Positive Phase I/II Hemophilia Study Data
by Zacks Equity Research
Sangamo (SGMO) and partner Pfizer announce encouraging data from a phase I/II study evaluating their gene therapy candidate for treating hemophilia A.
Why the Earnings Surprise Streak Could Continue for Pfizer (PFE)
by Zacks Equity Research
Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Top Research Reports for Pfizer, Royal Dutch Shell & Celgene
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), Royal Dutch Shell (RDS.A) and Celgene (CELG).
Novartis (NVS) to Acquire Subsidiary of IFM Therapeutics
by Zacks Equity Research
Novartis (NVS) is set to acquire IFM Tre, a subsidiary of IFM Therapeutics LLC, and strengthen its pipeline of drugs for chronic inflammatory disorders.
Spero Gets Fast Track Designation for SPR994, Shares Improve
by Zacks Equity Research
Spero???s (SPRO) SPR994 receives Fast Track designation by the FDA for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis.
Global Blood Focuses on Developing Lead Candidate Voxelotor
by Zacks Equity Research
Global Blood (GBT) is fast progressing on the development plans for its lead pipeline candidate, voxelotor for the treatment of sickle cell disease.
Biotech Stocks Outperform During Inversions: 5 Must Watch
by Tirthankar Chakraborty
An inverted yield curve signals a recession but it is often bullish for biotech stocks.
Sarepta (SRPT) Reports Positive Interim Results for DMD Drug
by Zacks Equity Research
Sarepta???s (SRPT) key pipeline candidate leads to statistically significant increase in dystrophin production in ESSENCE study. NDA to be filed mid-2019.
Pfizer (PFE) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $42.03, moving -0.92% from the previous trading session.
Calithera (CALA) Initiates Phase I/II Study of Telaglenastat
by Zacks Equity Research
Calithera (CALA) initiates a phase I/II study of the glutaminase inhibitor, telaglenastat (CB-839) in combination with Pfizer's poly adenosine diphosphate ribose polymerase inhibitor, Talzenna.
AbbVie's Psoriasis Drug Skyrizi Gets First Approval in Japan
by Zacks Equity Research
AbbVie's (ABBV) psoriasis drug Skyrizi gains the maiden approval in Japan for treating adults with plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis.
Ascendis Pivotal Growth Hormone Deficiency Study Data Positive
by Zacks Equity Research
Ascendis Pharma's (ASND) growth hormone deficiency candidate fares better than Pfizer's Genotropin in improving annual rate for increase in height in children.
Aerie (AERI) Starts Phase II Study on Eye Candidate in Japan
by Zacks Equity Research
Aerie (AERI) begins dosing in a phase II study on netarsudil ophthalmic solution in Japan for curbing high intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Shares Up.
Dow 30 Stock Roundup: AAPL Refreshes Product Lineup, BA Wins $327M Navy Order
by Swarup Gupta
The index traversed yet another volatile week but still managed to notch up strong gains.
Merck's Keytruda Picks Up Pace in Thriving Anti-PD-L1 Market
by Zacks Equity Research
Merck's (MRK) Keytruda is rapidly gaining strength as a key contributor to the company's top line. The Keytruda development program is also progressing well.
Pfizer/Merck KGaA End Bavencio+Talzenna Ovarian Cancer Study
by Zacks Equity Research
Pfizer (PFE) and Merck KGaA terminate a late-stage study on Bavencio and its new PARP inhibitor, Talzenna. This is the third ovarian cancer study failure in less than six months.
Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan
by Zacks Equity Research
Conatus (CNAT) concentrates on the development of its lead candidate, emricasan, for treating patients with fibrosis or cirrhosis caused by NASH.
Glaxo Presents Encouraging Data on Endometrial Cancer Drug
by Zacks Equity Research
Glaxo (GSK) presents encouraging data from phase I/II study on endometrial cancer drug, dostarlimab.
Pfizer (PFE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $42.32, moving +1.22% from the previous trading session.
Aerie (AERI) Starts Phase II Study on Eye Candidate AR-1105
by Zacks Equity Research
Aerie (AERI) begins dosing in a phase II study on AR-1105 for treating patients with macular edema due to retinal vein occlusion.
Allergan's Anti-Infective Gets FDA Nod for Pediatric Patients
by Zacks Equity Research
The FDA approves Allergan's (AGN) sNDA for the label expansion of its antibacterial medicine, Avycaz, to treat cUTI and cIAI in pediatric patients.
Bristol-Myers & Pfizer Release Phase IV Data on Eliquis
by Zacks Equity Research
Bristol-Myers (BMY) and partner Pfizer ) announce results from the phase IV - AUGUSTUS study evaluating Eliquis (apixaban) versus vitamin K antagonists (VKAs).
The Zacks Analyst Blog Highlights: Pfizer, Roche, Merck, Allergan and J&J
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Roche, Merck, Allergan and J&J
Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others
by Zacks Equity Research
Regulatory updates from J&J (JNJ), Merck (MRK), Roche (RHHBY), Pfizer (PFE) and others.
Dow 30 Stock Roundup: PFE's Herceptin Biosimilar Gets FDA Nod, VZ to Launch 5G Soon
by Swarup Gupta
The index enjoyed an encouraging week, buoyed by strong economic data.